Elena V Nikonova, 55Swarthmore, PA

2011025, Oct 13, 2011

Nov 6, 2009

13/127161

Louise C. Showe - Media PA, US
Michael Showe - Media PA, US
Andrew V. Kossenkov - Philadelphia PA, US
Elena Nikonova - Swarthmore PA, US

C40B 30/04
C40B 40/06
C07H 21/02

506 9, 536 2433, 506 16

Methods and compositions are provided for diagnosing or detecting a condition, e.g., lung disease in a mammalian subject by use of a micro-RNA expression level or an expression level profile of multiple miRNA in the peripheral blood mononuclear cells (PBMC) of the subject which is characteristic of COPD or NSCLC. Detection of changes in expression in specific miRNA biomarkers from that of a reference sample or miRNA expression profile are correlated with non-small cell lung cancer (NSCLC) and/or COPD and permit differentiation among healthy subjects, subjects with COPD and subjects with adenocarcinoma or squamous cell carcinoma.

2020037, Nov 26, 2020

Apr 30, 2020

16/862637

- Philadelphia PA, US
Michael SHOWE - Media PA, US
Andrew V. KOSSENKOV - Huntingdon Valley PA, US
Elena NIKONOVA - Swarthmore PA, US

C12Q 1/6886
C12Q 1/6883
G01N 33/50
G01N 33/574
C12Q 1/6809

Methods and compositions are provided for diagnosing or detecting a condition, e.g., lung disease in a mammalian subject by use of a micro-RNA expression level or an expression level profile of multiple miRNA in the peripheral blood mononuclear cells (PBMC) of the subject which is characteristic of COPD or NSCLC. Detection of changes in expression in specific miRNA biomarkers from that of a reference sample or miRNA expression profile are correlated with non-small cell lung cancer (NSCLC) and/or COPD and permit differentiation among healthy subjects, subjects with COPD and subjects with adenocarcinoma or squamous cell carcinoma.

2018025, Sep 6, 2018

Feb 26, 2018

15/905390

- Philadelphia PA, US
Michael SHOWE - Media PA, US
Andrew V. KOSSENKOV - Huntingdon Valley PA, US
Elena NIKONOVA - Swarthmore PA, US

C12Q 1/6886
G01N 33/574
C12Q 1/6809
C12Q 1/6883
G01N 33/50

Methods and compositions are provided for diagnosing or detecting a condition, e.g., lung disease in a mammalian subject by use of a micro-RNA expression level or an expression level profile of multiple miRNA in the peripheral blood mononuclear cells (PBMC) of the subject which is characteristic of COPD or NSCLC. Detection of changes in expression in specific miRNA biomarkers from that of a reference sample or miRNA expression profile are correlated with non-small cell lung cancer (NSCLC) and/or COPD and permit differentiation among healthy subjects, subjects with COPD and subjects with adenocarcinoma or squamous cell carcinoma.